Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma ...

On March 17, 2025, a bipartisan group of senators introduced two bills intended to decrease the cost of prescription drugs. The sponsors include ...

Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

John Green's new book highlights the history of tuberculosis, the world's deadliest infectious disease, which the Trump ...

Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...

Shares of Aurobindo Pharmaceuticals dropped 2% to a day's low of Rs 1,132.75, while Ipca Laboratories fell 2.7% to Rs ...

And Catalyst Pharmaceuticals stock is one of those that seems to be thriving. Catalyst is Thursday's selection for IBD 50 ...

Abbott today announced it has received CE Mark in Europe for the Volttm PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun ...